What is PRIME?

PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant. From 2020 – 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions.

Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.

Learn More

News & Events

25 January 2023

Two podcast episodes on insulin, diet and mental health

PRIME partners dr. Silke Matura (Goethe University Frankfurt) and Veerle van Gils (Maastricht University) have recorded two podcast episodes as part of the ECNP podcast series. In these two episodes they talk about their research as part of the PRIME study. In part 1 they discuss the role of dysfunctional insulin signaling as modulator of mental and non-mental chronic diseases. In part 2 they go further into the effects of lifestyle on cognition, and the various techniques used to measure different types of cognition. You can listen to the podcast on Spotify, iTunes, Buzzsprout, or here: https://www.ecnp.eu/Informationandnews/podcasts

More News